A
novel chemocentric approach to identifying cancer-relevant targets is
introduced. Starting with a large chemical collection, the strategy uses the
list of small molecule hits arising from a differential cytotoxicity screening
on tumor HCT116 and normal MRC-5 cell lines to identify proteins associated
with cancer emerging from a differential virtual target profiling of the most
selective compounds detected in both cell lines. It is shown that this smart
combination of differential in vitro and in silico screenings (DIVISS) is
capable of detecting a list of proteins that are already well accepted cancer
drug targets, while complementing it with additional proteins that, targeted
selectively or in combination with others, could lead to synergistic benefits
for cancer therapeutics. The complete list of 115 proteins identified as being
hit uniquely by compounds showing selective antiproliferative effects for tumor
cell lines is provided.
Source: A chemocentric approach to
the identification of cancer targets. Flachner B, Lörincz Z, Carotti A,
Nicolotti O, Kuchipudi P, Remez N, Sanz F, Tóvári J, Szabó MJ, Bertók B, Cseh
S, Mestres J (jmestres@imim.es), Dormán
G. PLoS One. 2012;7(4):e35582
Free
paper available at :
Aucun commentaire:
Enregistrer un commentaire